Navigation Links
Treating populations infected with HIV and latent TB could speed the emergence of drug-resistant TB

In 2005, 46 regional Ministers of Health in Africa declared that a dramatic rise in tuberculosis (TB) cases was cause for emergency. In some African countries, annual TB case notifications have increased as much as four-fold over the past 15 years. The main culprit? The emergence of HIV. When individuals are infected with both HIV and TB, they are more likely to progress from latent TB infection to active TB.

To combat the problem, the World Health Organization currently recommends that as part of HIV/AIDS programs, patients infected with both HIV and TB be treated with isoniazid, an antimicrobial, as a preventive therapy to reduce the risk that TB will progress from latent infection to active disease. However, researchers from the Harvard School of Public Health (HSPH) and a team of collaborators believe that strategy has flaws. Their findings appear in the advance online edition of the May 2, 2006 issue of Proceedings of the National Academy of Sciences.

The researchers, led by Ted Cohen, doctoral student at HSPH, and senior author Megan Murray, Assistant Professor of Epidemiology, developed a mathematical model to describe the projected impact of isoniazid preventive therapy (IPT) programs on the transmission dynamics of drug-resistant TB in areas where community-wide preventive therapy may be used as a strategy to control TB. They concluded that the implementation of IPT targeted to people co-infected with HIV and TB may also have the perverse effect of speeding the emergence of drug-resistant TB.

"We're not saying isoniazid preventive therapy policies are ill-advised," said Cohen. "But we think they need to be coupled with an understanding that large-scale IPT programs should be ready to diagnose and treat individuals with drug-resistant TB as part of the programs."


'"/>

Source:Harvard School of Public Health


Page: 1

Related biology news :

1. Potential Drug Target For Treating Cocaine Abuse Found
2. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
3. Opiates Better Than Sedatives For Treating Newborns In Withdrawal
4. Measuring the impact of post-genomics on Mediterranean populations
5. A new study examines how shared pathogens affect host populations
6. New discovery: Molecular variation in one gene affects the growth of natural populations
7. Escapee farmed salmon infiltrate fitter wild populations
8. Researchers make progress in studying genetic traits of India-born populations
9. Commercial fishing causes dangerous fluctuations in fish populations
10. Ongoing collapse of coral reef shark populations
11. Antarctic warming to reduce animals at base of ecosystem, shift some penguin populations southward
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... ... at the 2016 annual meeting of the North American Spine Society (NASS)1 ... patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ ... these new tools and assays, and their applicability in drug safety assessment, for ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a leading ... a collaboration with the Heidelberg University Hospital and the German Cancer Research Center ... the company’s successful launch of its CATS (Capture and Amplification by Tailing ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
Breaking Biology Technology: